Betta Pharmaceuticals and Shengsi Biotech have reached a strategic cooperation and obtained exclusive distribution rights for the FRSW117 product in the Greater China regionZhitong·Nov 2, 2025 at 03:09 AM贝达药业
Afternoon of the third day of the 2025 National Conference: Representatives from companies such as Novartis, Roche, and Betta Pharmaceuticals enterZhitong·Nov 1, 2025 at 01:29 AMRHHBY+0.55%贝达药业
BETTA PHARMACEUTICALS: The company currently does not have exclusive agency for foreign productsZhitong·Oct 17, 2025 at 03:33 AM贝达药业300558-3.86%
New Stock News | Betta Pharmaceuticals has submitted its application to the Hong Kong Stock Exchange and has successfully transformed into a "platform-based pharmaceutical company."Zhitong·Sep 29, 2025 at 05:51 PM贝达药业
Beijing Beida Pharmaceutical Co., Ltd. submitted a listing application to the Hong Kong Stock ExchangeZhitong·Sep 29, 2025 at 09:39 AM贝达药业
BETTA PHARMACEUTICALS: Will strive for more new drug approvals in high-incidence tumor areas such as lung cancer and breast cancerWallstreetcn·Sep 2, 2025 at 08:30 PM300558-3.86%贝达药业
BETTA PHARMACEUTICALS: The first prescription for Enasidenib Hydrochloride Capsules has been issued in the United StatesZhitong·Aug 27, 2025 at 05:40 AM贝达药业300558-3.86%
BETTA PHARMACEUTICALS: Clinical research on the postoperative adjuvant indication of ensartinib has made progressZhitong·Aug 24, 2025 at 07:04 PM贝达药业300558-3.86%
BETTA PHARMACEUTICALS: Currently, there is no need to provision for the issuance loss of Heyuan BiotechnologyZhitong·Aug 24, 2025 at 01:50 AM300558-3.86%贝达药业
BETTA PHARMACEUTICALS released its performance for the first half of the year, with a net profit attributable to the parent company of 140 million yuan, a decrease of 37.53%Zhitong·Aug 19, 2025 at 05:59 AM贝达药业300558-3.86%
BETTA PHARMACEUTICALS: MCLA-129 is currently exploring indications in the field of lung cancerZhitong·Aug 18, 2025 at 11:47 PM300558-3.86%贝达药业
BETTA PHARMACEUTICALS: The company has corresponding preclinical project establishment for the KRAS targetZhitong·Jul 19, 2025 at 05:04 AM300558-3.86%贝达药业
Benda Pharmaceutical: HeYuan Biotech's new drug Aofumin has been approved for market launchZhitong·Jul 18, 2025 at 06:41 AM贝达药业
BETTA PHARMACEUTICALS: Has reached a strategic cooperation with Boryung Biopharma, and the company’s exclusive distribution of Anruize has officially launched nationwide salesZhitong·Jul 14, 2025 at 07:50 AM贝达药业300558-3.86%
BETTA PHARMACEUTICALS: The company is accelerating the overseas commercial plan for ensartinibZhitong·Jul 4, 2025 at 03:45 AM300558-3.86%贝达药业
